Loading...
Arg-Leu-Tyr-Glu tetrapeptide inhibits tumor progression by suppressing angiogenesis and vascular permeability via VEGF receptor-2 antagonism
The tetrapeptide Arg-Leu-Tyr-Glu (RLYE) is known to inhibit vascular endothelial growth factor-A (VEGF-A)-induced angiogenesis in vitro. Herein, we examined its underlying mechanism and antitumor activity associated with vascular remodeling. RLYE inhibited VEGF-A-induced angiogenesis in a mouse mode...
Saved in:
| Published in: | Oncotarget |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Impact Journals LLC
2016
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5355302/ https://ncbi.nlm.nih.gov/pubmed/28052029 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.14343 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|